In addition, recent data published by Wittenbecher et al. showed circulating IGFBP2 serum concentration to be associated with FLI, serum triglyceride, ALT, and γGT levels, as well as a high risk for the development of metabolic complications in patients without obesity [40], further indicating a potential link to IGFBP2 serum concentration and liver function. The gene discussed is IGFBP2; the disease is obesity disorder.